Bioventus Inc. Stock Price, News & Analysis

Bioventus Inc. (Nasdaq: BVS) has announced a strategic investment in Trice Medical, securing exclusive sales and distribution rights for Trice’s products outside the US. This investment includes a co-development agreement to integrate Trice’s technologies with Bioventus’ peripheral nerve stimulation offerings, enhancing product adoption. Trice, known for its innovative surgical devices, aims to improve patient recovery and reduce costs. This alliance aligns with Bioventus' strategy to expand its portfolio in the sports medicine and orthopedic sectors.

Bioventus (Nasdaq: BVS) has appointed Dave Crawford as Vice President, Investor Relations and Treasurer, bringing over 20 years of finance experience to the role. Previously with Avanos Medical, Crawford has a strong background in finance and treasury from Kimberly-Clark and Eli Lilly. His MBA is from Duke University, and he holds a Bachelor’s in Accounting from Notre Dame. The company continues to focus on delivering clinically proven, cost-effective products for healing.

SV Health Investors, a global healthcare investment firm, announced significant realizations from its growth equity portfolio. HillRom acquired Bardy Diagnostics on August 6, enhancing its ambulatory cardiac monitoring services. Healthify agreed to be acquired by WellSky, focusing on integrating social services into healthcare. Additionally, Bioventus announced a cash and stock deal to acquire Misonix, a company supported by SV since 2017. SV's initiatives align with its strategy of driving growth and enhancing patient access while managing $2.6B in assets.

Bioventus reported Q2 financial results for 2021, achieving net sales of $109.8 million, an increase of 89.3% year-over-year. This includes $97.9 million from legacy operations and $11.9 million from Bioness Inc. acquisition. Despite a net loss of $10.8 million, this reflects an increase of 80.3% year-over-year. Adjusted EBITDA rose to $19.9 million, up 186.5% year-over-year. The company updated its full-year guidance, projecting net sales growth of 26% to 29% and increased total addressable market to $15 billion.

Bioventus Announces Acquisition of Misonix

Bioventus will acquire Misonix in a cash-and-stock deal valued at approximately $518 million, enhancing its product portfolio and revenue. The transaction involves Misonix stockholders choosing between 1.6839 shares of Bioventus stock or $28.00 in cash. Once completed, the merger aims to accelerate growth opportunities, adding nearly $80 million in revenue for 2021 and generating $20 million in annual cost synergies by year two. The deal awaits regulatory and stockholder approvals, expected to finalize in Q4 2021.

Bioventus Inc. (Nasdaq: BVS) reported preliminary second quarter net sales of $108 million to $110 million, reflecting an impressive 86.2% to 89.7% year-over-year growth. This includes $96.5 million to $98.0 million from legacy operations and $11.5 million to $12.0 million from the recent acquisition of Bioness Inc. Updated full-year guidance anticipates net sales of $405 million to $415 million, marking a 26% to 29% increase. Bioventus also announced its intention to acquire Misonix, expanding its product portfolio in regenerative medicine.

DURHAM, N.C., July 27, 2021 - Bioventus (Nasdaq: BVS) will participate in two virtual conferences: the Canaccord Genuity 41st Annual Growth Conference on August 12 at 3:30 p.m. ET and the Morgan Stanley Virtual Global Healthcare Conference on September 10 at 9:30 a.m. ET. Presentation materials will be available in the investor relations section of the Bioventus website before each event, alongside live audio webcasts and replays accessible for 30 days. Bioventus focuses on clinically proven products for active healing.

Bioventus (Nasdaq: BVS) has appointed Mary Kay Ladone to its Board of Directors, effective July 15, 2021. Ladone, a seasoned executive with over 30 years in global healthcare, will also serve on the Audit and Risk Committee and the Compensation Committee. CEO Ken Reali noted her expertise in strategic planning and investor relations, which will aid Bioventus in its growth strategy focused on new product development and M&A. Ladone previously held positions at Hillrom Holdings and Baxalta, enhancing her credentials in corporate development and investor relations.

Bioventus (BVS) has launched OSTEOAMP SELECT Flowable, an innovative allograft bone graft substitute aimed at enhancing surgical outcomes in spine fusion and other procedures. This product is 100% allograft, free from synthetic carriers, and is designed for smooth handling and effective retention at the grafting site. Available in three sizes, the flowable allograft is terminally sterilized and processed to meet stringent tissue banking standards. The launch follows a limited release in select markets earlier this year, with enthusiastic endorsements from leading spine surgeons highlighting its utility in minimally invasive surgeries.